Claritev (NYSE:CTEV) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Claritev (NYSE:CTEV – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $33.6667.

CTEV has been the subject of several recent analyst reports. Wells Fargo & Company decreased their target price on Claritev from $30.00 to $22.00 and set an “equal weight” rating for the company in a research note on Thursday, March 19th. Citigroup restated a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. Barclays started coverage on shares of Claritev in a research report on Friday, April 24th. They set an “overweight” rating and a $28.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Finally, Piper Sandler set a $61.00 target price on shares of Claritev in a research note on Wednesday, June 3rd.

Get Claritev alerts:

View Our Latest Research Report on Claritev

Hedge Funds Weigh In On Claritev

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Arini Captial Management Ltd acquired a new stake in shares of Claritev in the 4th quarter valued at about $64,291,000. Public Investment Fund acquired a new position in Claritev during the 3rd quarter worth approximately $68,009,000. Beach Point Capital Management LP boosted its holdings in Claritev by 77.4% in the fourth quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after acquiring an additional 329,424 shares in the last quarter. Vanguard Group Inc. acquired a new stake in Claritev in the third quarter valued at approximately $27,483,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Claritev by 17.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 262,318 shares of the company’s stock valued at $11,214,000 after acquiring an additional 39,845 shares in the last quarter. Institutional investors own 87.15% of the company’s stock.

Claritev Trading Down 4.0%

CTEV stock opened at $31.85 on Wednesday. The firm has a market cap of $543.04 million, a PE ratio of -1.84 and a beta of 0.69. The stock has a 50-day moving average price of $27.18 and a 200-day moving average price of $25.27. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07.

Claritev Company Profile

(Get Free Report)

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.

Featured Articles

• Five stocks we like better than Claritev
• Apple and Broadcom Forge a Decade-Long Silicon Fortress
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic

Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.